Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion
July 8 () - Hong Kong-listed Sino Biopharmaceutical said on Wednesday ‌it has granted AstraZeneca ‌the rights to develop a drug ​designed to treat chronic respiratory diseases outside China for total payments of up to $1. • Under ‌the deal, â AstraZeneca gets an exclusive license to develop, manufacture â and commercialize the drug — TQC3721 — outside China, with additional ​exclusive global ​rig…
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief